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was assessed by using the SF-36 questionnaire among the
ID subjects and a randomly selected control group of sub-
jects not suffering from ID (520 persons). RESULTS: The
population surveyed was representative of the French
population in terms of age, sex, and geographic living
area. Patients suffering from ID were similar to the
control group in terms of age, sex, and geographic living
area. The annual prevalence of ID was estimated: 8.8%,
IC 95% = [7.8%; 9.8%]. The SF-36 score of mental
health was signiﬁcantly lower in the ID population: 45.8
versus 48.0 in the control group (p < 0,001). The SF-36
score of physical health was not signiﬁcantly different.
CONCLUSION: The annual prevalence of inﬂammatory
dermatitis is estimated at 9% in French adult population.
People suffering from inﬂammatory dermatitis have a sig-
niﬁcant impact on the mental health dimension of quality
of life but not on physical dimension.
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OBJECTIVE: A common approach to the problem of
interpreting the clinical implications of quality of life
(QoL) scores is to utilize the concept of minimal impor-
tant difference (MID). MID emphasises both the primacy
of patient preferences and the relation between QoL
scores and treatment change. The study purpose is to
illustrate how discrete choice analysis (DCA) could be
used to estimate the relation between QoL and patient
preferences for treatment change. METHODS: A 28-item
atopic dermatitis (AD) QoL instrument was applied to
102 subjects enrolled in a pivotal trial comparing two
alternative AD treatments. Four QoL assessments were
made over 12 months. Subjects were also asked to indi-
cate the extent to which the disease was under control.
Their responses were dichotomized into a variable, which
indicated whether subjects were inclined to seek treat-
ment change, or not. DCA was used to estimate the rela-
tion between probability of treatment change and QoL
scores. RESULTS: QoL scores were found to be a statis-
tically signiﬁcant predictor of the probability that a
subject would seek a treatment change (p < 0.0001 in
each case). The sign on the QoL coefﬁcient was in line
with prior expectations. For both treatments, the proba-
bility that a subject would seek a treatment change
declined over time (from 0.63 to 0.42 for active treat-
ment; 0.63 to 0.57 for comparator). However, the prob-
ability for the new treatment under investigation was
lower at the end of the trials than for the comparator.
CONCLUSIONS: While our analysis is illustrative and
exploratory, the results suggest that DCA offers a promis-
ing approach to the interpretation of QoL scores. By
modeling the direct relation between QoL scores and a
patient’s desire for treatment change, the approach dis-
penses with the need for anchor measures, the interpre-
tation of which is often unclear.
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OBJECTIVES: The objective of the analysis is to evalu-
ate the willingness to pay for topical psoriasis treatment
in Denmark. METHODS: A stated preference method—
discrete choice experiment (DCE) was applied as a postal
survey to 700 members of the Danish Psoriasis Associa-
tion. The respondents were asked to choose between two
hypothetical treatment options. The treatment options
were described by six attributes: Number of products, fre-
quency of application, visual effects, non-visual effects,
three types of side effects and monthly cost. Through
logistic regression it was possible to extract the willing-
ness-to-pay of each attribute and for speciﬁc marketed
treatment options (deﬁned by these attributes).
RESULTS: The survey had a high response rate (73%, or
N = 510), and showed the highest willingness-to-pay for
avoidance of two named side effects (irritated skin and
thin skin) followed by visual effect of the treatment. After
adjusting results of the logistic regression model for
income, the willingness to pay for the best possible treat-
ment option relative to the worst possible treatment
option was DKK 4443 (=€597) per month. The willing-
ness to pay for for a newly launched topical treatment
option containing calcipotriol and bethamethasone
(Daivobet) would thus be DKK 4043 (=€543) compared
to an estimated monthly treatment cost of DKK 683 
(=€92). Thus, the societal welfare gain of a month of
Daivobet treatment is DKK 3360 (=€452). CONCLU-
SION: The survey showed high willingness to pay among
a group of Danish psoriasis patients, especially for
avoided side effects and effective treatment. For a single
product (calcipotriol/bethamethasone (Daivobet)), the
willingness-to-pay proved more than fourfold as high as
the treatment cost.
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OBJECTIVES: Evaluating quality-of-life (QoL) of atopic
dermatitis patients and parents of children with atopic
dermatitis as well as patients’ preferences during and after
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a skin deterioration (ﬂare). METHODS: Multi-centre,
cross-sectional, prospective QoL study. Information
including demographic and disease characteristics was
collected with semi-structured patient questionnaire 
and by chart abstraction. Disease-speciﬁc instruments:
PIQoL-AD (Parents Index Quality of Life—Atopic Der-
matitis; score: 0–28 points) for parents of children up to
8 years, QoLIAD (Quality of Life Index Atopic Dermati-
tis; score: 0–25 points) for patients over 16 years. CDLQI
(Children Dermatology Life Quality Index; score: 0–30
points) was used for patients aged 9–16 years. Higher
scores indicate greater impairment of QoL. EQ-5D was
used to assess preferences (utilities) of patients over 16
years. RESULTS: A total of 193 patients enrolled at 
16 centers (10 ofﬁce-based dermatologists, 4 ofﬁce-based
paediatricians, 1 outpatient unit of a dermatology hospi-
tal, 1 patient organization) sent back the questionnaires.
Mean age (range): 23 years (1–71 years), 63% female.
27% of the patients had a mild, 38% a moderate and
35% a severe course of disease. Median duration of
current ﬂare: 12 days. Mean utility value during a ﬂare
was 0.69 (SD 0.26). After ﬂare mean utility value rose up
to 0.82 (SD 0.17). Atopic dermatitis-speciﬁc instruments
(PIQoL-AD/QoLIAD) showed reductions in QoL during
a ﬂare in comparison to the period after ﬂare: 10.2 (SD
7.3) vs. 6.4 (SD 6.1)/11.4 (SD 7.2) vs. 7.5 (SD 6.6).
Patients aged 9–16 years (CDLQI) reported comparable
impairment of QoL during (9.8, SD 3.8) and after a ﬂare
(9.6, SD 3.9). CONCLUSIONS: Patients’ and parents’
QoL is reduced considerably during a ﬂare of atopic der-
matitis. Health status (utility value) of patients during a
ﬂare is comparable to health status of patients with other
chronic diseases like e.g. diabetes type II.
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OBJECTIVES: To estimate the incremental costs and
incremental health effects of replacing methotrexate
(MTX) by alefacept (Amevive) in patients with moderate
to severe psoriasis (PASI-score 10+). METHODS: A total
of 36 patients with moderate to severe psoriasis were
interviewed about quality of life and treatment costs.
Disease severity was measured by PASI-score (Psoriasis
Area and Severity Index) while quality of life was mea-
sured by a multiattribute utility instrument (15D) and a
disease speciﬁc instrument (DLQI-N). Cost of psoriasis
therapy during the past three months was estimated on
the basis of patients’ utilization reports and unit costs. A
Markov model with 4 health states based on PASI-score
(0, 1–9, 10–19, 20+), 12 weeks cycles and 2 years time
horizon was developed. Transition probabilities were
derived from published clinical trials (MTX and ale-
facept) and websites (alefacept), but no head-to-head
trials were available. The beneﬁt from psoriasis therapy
was expressed in terms of QALYs, and sensitivity analy-
ses were used to explore the robustness of the results.
RESULTS: Quality of life was estimated at 0.94, 0.91,
0.88, and 0.77 in the four PASI-groups. Average 3 months
psoriasis treatment costs were $384, $509, and $960 for
patients with PASI-score 1–9, 10–19, 20+ respectively. In
the base case, alefacept has higher costs and lower health
beneﬁt, and this result was fairly robust to a wide range
of changes in the model parameters. Only when all para-
meters values were assumed as favourable as conceivable
for alefacept and as unfavourable as conceivable for
MTX, the cost per QALY came down to $76,400. CON-
CLUSION: Alefacept seems to represent greater costs and
smaller health beneﬁts than MTX in patients with mod-
erate to severe psoriasis. There is an urgent need to
conﬁrm these results in head-to-head trials of MTX and
alefacept.
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OBJECTIVE: To describe quality of life (QoL) and
patients’ preferences in psoriasis patients with current
skin deterioration and 6 weeks later after subsequent
therapy. METHODS: Prospective, multi-center, cross-sec-
tional, quality of life study combined with a cost-of-illness
study. Patients (over 17 years; with moderate and severe
course of disease) were enrolled consecutively by 12
ofﬁce-based dermatologists and by 5 outpatient depart-
ments in dermatology hospitals. Instruments: DLQI (Der-
matology Life Quality Index; sum score: 0–30 points; 0
= no reductions in QoL), EQ-5D, semi-structured patient
questionnaire. RESULTS: A total of 227 patients were
enrolled. 197 sent back the quality of life questionnaire
part A (within current skin deterioration) and 151
patients part B (6 weeks later). Mean age were 47 years,
55% were male. Mean DLQI score during the current
skin deterioration accounted 9.3 (SD 6.8) and varied from
0 to 27 points; 6 weeks later DLQI score decreased to 6.8
(SD 5.2). The mean utility value was 0.79 (SD 0.18) at
enrollment due to current skin deterioration and showed
the same ﬁgure 6 weeks later (0.80, SD 0.17). DLQI score
indicated greater reductions of QoL due to a current skin
deterioration in patients with severe course of psoriasis
(10.4, SD 7.1) than in patients with moderate form of
psoriasis (8.4, SD 6.4). Mean DLQI score decreased from
9.1 (SD 6.8) to 7.0 (SD 5.7) in patients with topical treat-
ment and/or phototherapy within 6 weeks. In patients
treated with systemic medication additionally, mean
DLQI score fell from 8.3 (SD 5.6) to 5.7 (SD 4.0). CON-
CLUSIONS: The considerable reduction in QoL due to a
